விழித்திரை ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from விழித்திரை ஆராய்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In விழித்திரை ஆராய்ச்சி Today - Breaking & Trending Today

Unity, on the rebound after catastrophe, shows promising results in early eye disease trial

Unity Biotechnology CEO Anirvan Ghosh, Ph.D. (Unity)
Nearly a year after dropping its lead program and sinking its stock, Unity Biotechnology appears to be coming back on track with positive data in its phase 1 study in patients with advanced vascular eye disease.
The anti-aging biotech said Tuesday its small-molecule inhibitor of Bcl-xL, a senolytic therapeutic, was well tolerated in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD).
Unity shares were up about 9% in early trading Tuesday morning.
The study of UBX1325 was conducted in patients for whom anti–vascular endothelial growth factor (anti-VEGF) therapy was not considered to be beneficial anymore. Anti-VEGF treatments include Roche s Lucentis, Regeneron s Eylea, Novartis Beovu and Roche s Avastin. ....

United States , Roche Lucentis , Roche Avastin , Anirvan Ghosh , Novarti Beovu , Jeffrey Heier , Regeneron Eylea , Retina Research At Ophthalmic Consultants Of Boston , Vitreoretinal Service , Unity Biotechnology , Retina Research , Ophthalmic Consultants , ஒன்றுபட்டது மாநிலங்களில் , ஜெஃப்ரி ஹேஎர் , விழித்திரை ஆராய்ச்சி இல் கண் ஆலோசகர்கள் ஆஃப் போஸ்டன் , விதிறெோரேதினாள் சேவை , ஒற்றுமை உயிரி தொழில்நுட்பவியல் , விழித்திரை ஆராய்ச்சி , கண் ஆலோசகர்கள் ,

Lineage Cell Therapeutics : to Host Webinar With Therapeutic Area Experts to Discuss Retinal Tissue Restoration Observed in Dry AMD Patients Treated With OpRegen®

Webinar Scheduled for June 10, 2021 at 4pm Eastern Time / 1pm Pacific Time
. | June 3, 2021 ....

Wills Eye Hospital , United States , Nuevo Leóx , Harvard University , University Of Cincinnati , Hebrew University , Thomas Jefferson University , Comunidad Autonoma De Cataluna , Eyal Banin , Los Angeles , Vail Vitrectomy , Christopherd Riemann , Jordi Mon , Michaels Ip , Brandon Lujan , Cincinnati Academy Of Medicine , University Of Pennsylvania Scheie Eye Institute , Casey Reading Center , Hadassah School Of Medicine , Casey Eye Institute , Retina Measures Group , Cincinnati Eye Institute , University Of Barcelona , Monterrey Institute Of Technology , Retina Research , National Institutes Of Health ,

Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors

Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
By
Staff
58 seconds ago
NEW YORK–(BUSINESS WIRE)–#EYEN Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the appointment of renowned ophthalmologist and scientific leader, Julia Haller, M.D., to its Board of Directors.
“We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” commented Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia. “We believe that Dr. Haller’s decades of experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader will be invaluable to the Eyenovia team as we strive to advance our late-stage ophthalmic pipeline and work towards our near-term cli ....

Wills Eye Hospital , United States , Thomas Jefferson University , Sam Choinski , Eric Ribner , Julia Haller , John Gandolfo , Charlesl Schepens , Katharine Graham , Johns Hopkins , Sean Ianchulev , Ophthalmologica Internationalis , Society Of Heed Fellows , Eyenovia Inc , Philadelphia Medical Society , Bristol Myers Squibb Company , National Academy Of Medicine , Johns Hopkins Society Of Scholars , American Ophthalmological Society Council , Surgical Association , American Society Of Retina Specialists , Retina Society , Macula Society , American Academy Of Ophthalmology Foundation , Wilmer Eye Institute At Johns Hopkins , Services For The Blind ,

REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD

RGX-314 using subretinal delivery continues to be generally well-tolerated at all dose levels
Positive interim update from Cohorts 4 and 5 at 1.5 years after RGX-314 administration
Durable treatment effect observed with stable visual acuity, decreased retinal thickness, and reductions in anti-VEGF injection burden
Long-term, durable treatment effect over three years demonstrated in Cohort 3
Mean improvement in vision and stable retinal thickness
50% of patients (3/6) remain anti-VEGF injection-free over three years; 67% of patients (4/6) are anti-VEGF injection-free from nine months to three years
ATMOSPHERE™, the first of two planned pivotal trials for RGX-314, is active and enrolling
REGENXBIO Inc. (Nasdaq: RGNX) reported at the Angiogenesis, Exudation, and Degeneration 2021 conference additional positive interim data from Cohorts 4 and 5 of its RGX-314 Phase I/IIa trial for the treatment of wet age-related macular degeneration (wet AMD), and C ....

United States , David Rosen , Brendan Burns , Tricia Truehart , Steve Pakola , Technology Platform , Technology Platform Licensees , Clearside Biomedical Inc , Exchange Commission , Corporate Communications , Retina Research At Wills Eye Hospital , Securities Exchange , Long Term Follow Up , Chief Medical Officer , Retina Research , Wills Eye Hospital , Mid Atlantic Retina , Safety Update , Best Corrected Visual Acuity , Study Data , Clearside Biomedical , Clinical Trial , Platform Licensees , Securities Act , Securities Exchange Act , Financial Condition ,

Genentech Could Regain the Blindness-Related Disease Market with New Treatment

Published: Feb 12, 2021
By Kate Goodwin
After announcing topline data from two identical Phase III trials,
Roche’s Genentech has doubled down on data and is now
Faricimab is an injectable treatment to maintain the vision of patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). These are two of the leading causes of blindness with nAMD responsible for 90% of all blindness resulting from AMD.
Genetech’s Lucentis was the
first FDA-approved drug proven to restore sight in nAMD patients. Since 2006 it had been a game-changer in the ophthalmology world. But then Regeneron’s Eylea came in as the main contender and the companies have had to share the market since 2011. ....

United States , Roche Genentech , Levi Garraway , Genetech Lucentis , Jeffrey Heier , Regeneron Eylea , Retinal Research At Ophthalmic Consultants Of Boston , Global Product Development , Competitor Eylea , Retinal Research , Ophthalmic Consultants , Global Product , Genentech Could Regain The Blindness Related Disease Market With New Treatment , ஒன்றுபட்டது மாநிலங்களில் , ரோச் ஜெநிஂடெக் , லெவி க்யாரவ , ஜெஃப்ரி ஹேஎர் , விழித்திரை ஆராய்ச்சி இல் கண் ஆலோசகர்கள் ஆஃப் போஸ்டன் , உலகளாவிய ப்ராடக்ட் வளர்ச்சி , விழித்திரை ஆராய்ச்சி , கண் ஆலோசகர்கள் , உலகளாவிய ப்ராடக்ட் , ஜெநிஂடெக் முடியும் மீண்டும் பெறுங்கள் தி குருட்டுத்தன்மை தொடர்புடையது நோய் சந்தை உடன் புதியது சிகிச்சை ,